Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 459

1.

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network.

Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18.

2.

Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Jin H, Shih PA, Golshan S, Mudaliar S, Henry R, Glorioso DK, Arndt S, Kraemer HC, Jeste DV.

J Clin Psychiatry. 2013 Jan;74(1):10-8. doi: 10.4088/JCP.12m08001. Epub 2012 Nov 27.

3.

Switching antipsychotic medications: not enough, too often, or just right?

Weiden PJ.

Am J Psychiatry. 2011 Sep;168(9):882-4. doi: 10.1176/appi.ajp.2011.11060958. No abstract available.

PMID:
21890800
4.

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.

Stroup TS, Byerly MJ, Nasrallah HA, Ray N, Khan AY, Lamberti JS, Glick ID, Steinbook RM, McEvoy JP, Hamer RM.

Schizophr Res. 2013 May;146(1-3):190-5. doi: 10.1016/j.schres.2013.01.013. Epub 2013 Feb 21.

5.

Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK.

JAMA. 2009 Oct 28;302(16):1765-73. doi: 10.1001/jama.2009.1549. Erratum in: JAMA. 2009 Dec 2;302(21):2322.

6.

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy.

Kane JM, Correll CU, Goff DC, Kirkpatrick B, Marder SR, Vester-Blokland E, Sun W, Carson WH, Pikalov A, Assunção-Talbott S.

J Clin Psychiatry. 2009 Oct;70(10):1348-57. doi: 10.4088/JCP.09m05154yel.

PMID:
19906340
7.

Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems.

Mukundan A, Faulkner G, Cohn T, Remington G.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006629. doi: 10.1002/14651858.CD006629.pub2. Review.

PMID:
21154372
8.

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.

J Clin Psychiatry. 2008 Jul;69(7):1046-56.

PMID:
18605811
9.

Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.

Garman PM, Ried LD, Bengtson MA, Hsu C, McConkey JR.

J Am Pharm Assoc (2003). 2007 May-Jun;47(3):373-8.

PMID:
17510032
10.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
11.

Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.

Kolotkin RL, Corey-Lisle PK, Crosby RD, Kan HJ, McQuade RD.

Eur Psychiatry. 2008 Dec;23(8):561-6. doi: 10.1016/j.eurpsy.2008.01.1421. Epub 2008 Apr 18.

PMID:
18374544
12.

A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.

Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, Leonova-Edlund J, Leong RW, Brecher M.

J Clin Psychiatry. 2009 Apr;70(4):487-99. Epub 2009 Apr 7.

13.
14.

Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.

Newcomer JW, Meyer JM, Baker RA, Eudicone JM, Pikalov A, Vester-Blokland E, McQuade RD, Crandall DT, Carson WH, Marcus RN, L'italien G.

Schizophr Res. 2008 Dec;106(2-3):300-7. doi: 10.1016/j.schres.2008.09.002. Epub 2008 Oct 29.

15.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S.

Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Review.

PMID:
24249315
16.

A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.

Lee SY, Park MH, Patkar AA, Pae CU.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):490-6. doi: 10.1016/j.pnpbp.2010.12.003. Epub 2010 Dec 10.

PMID:
21146575
17.

Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.

Wang LJ, Ree SC, Huang YS, Hsiao CC, Chen CK.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jan 10;40:260-6. doi: 10.1016/j.pnpbp.2012.10.010. Epub 2012 Oct 18.

PMID:
23085073
18.

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.

Awad G, Hassan M, Loebel A, Hsu J, Pikalov A, Rajagopalan K.

BMC Psychiatry. 2014 Feb 23;14:53. doi: 10.1186/1471-244X-14-53.

19.

The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia.

Meyer JM, Rosenblatt LC, Kim E, Baker RA, Whitehead R.

J Clin Psychiatry. 2009 Mar;70(3):318-25. Epub 2008 Dec 16.

PMID:
19192469
20.

Supplemental Content

Support Center